Want to see LFCR full AI Analyst Report?
LFCR Stock Chart & Stats
$7.71
-$0.17(-2.79%)
At close: 4:00 PM EST
$7.71
-$0.17(-2.79%)
Day’s Range― - ―
52-Week Range$3.63 - $8.98
Previous CloseN/A
Volume140.23K
Average Volume (3M)193.49K
Market Cap
$190.92M
Enterprise Value$336.40M
Total Cash (Recent Filing)$20.80M
Total Debt (Recent Filing)$150.14M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Aug 06, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding37,509,407
10 Day Avg. Volume157,038
30 Day Avg. Volume193,489
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)175.14
Price to Sales (P/S)1.82
P/FCF Ratio-17.18
Enterprise Value/Market Cap1.76
Enterprise Value/Revenue2.49
Enterprise Value/Gross Profit7.98
Enterprise Value/Ebitda-327.55
Forecast
1Y Price Target
$6.50Price Target Upside-15.69% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.02
Revenue Forecast (FY)$122.18M
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistent positive operating and free cash flow provides a durable internal funding source to cover operating needs, service debt, and invest in capacity or R&D. This improves resilience during revenue cyclicality and reduces reliance on external financing over the medium term.
Specialized CDMO NicheA focused sterile injectable CDMO model with end-to-end formulation, aseptic fill-finish and analytical services creates high technical barriers to entry, long onboarding cycles, and sticky customer relationships, supporting recurring revenue and pricing power over time.
Talent/ Governance ContinuityApproval of a refreshed stock incentive plan and re-election of directors signals governance continuity and gives management a tool to attract and retain specialized talent. Stronger retention reduces operational risk in complex manufacturing and supports execution of multi-year customer programs.
Bears Say
High LeverageVery high debt relative to equity constrains financial flexibility, raises refinancing and interest-rate risk, and limits capacity to fund inorganic growth or withstand demand shocks. Elevated leverage amplifies downside in prolonged revenue weakness or margin pressure.
Persistent Net LossesSubstantial net losses and weak profitability despite improving cash flow indicate core earnings power remains unproven. Continued negative margins reduce retained earnings, impede equity rebuild, and make long-term reinvestment or dividend initiation unlikely until sustained profits appear.
Revenue Lumpiness / Utilization RiskRevenue and margins depend on lumpy contract manufacturing campaigns and capacity utilization, making topline and free cash flow volatile. This utilization sensitivity complicates forecasting, increases downside in demand troughs, and can leave fixed costs under-absorbed for extended periods.
Lifecore Biomedical News
LFCR FAQ
What was Lifecore Biomedical, Inc.’s price range in the past 12 months?
Lifecore Biomedical, Inc. lowest stock price was $3.63 and its highest was $8.98 in the past 12 months.
What is Lifecore Biomedical, Inc.’s market cap?
Lifecore Biomedical, Inc.’s market cap is $190.92M.
When is Lifecore Biomedical, Inc.’s upcoming earnings report date?
Lifecore Biomedical, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 33 days.
How were Lifecore Biomedical, Inc.’s earnings last quarter?
Currently, no data Available
Is Lifecore Biomedical, Inc. overvalued?
According to Wall Street analysts Lifecore Biomedical, Inc.’s price is currently Overvalued.
Does Lifecore Biomedical, Inc. pay dividends?
Lifecore Biomedical, Inc. does not currently pay dividends.
What is Lifecore Biomedical, Inc.’s EPS estimate?
Lifecore Biomedical, Inc.’s EPS estimate is -0.22.
How many shares outstanding does Lifecore Biomedical, Inc. have?
Lifecore Biomedical, Inc. has 37,509,407 shares outstanding.
What happened to Lifecore Biomedical, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Lifecore Biomedical, Inc.?
Currently, no hedge funds are holding shares in LFCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lifecore Biomedical Stock Smart Score
Company Description
Lifecore Biomedical, Inc.
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
LFCR Stock 12 Month Forecast
Average Price Target
$6.50
▼(-15.69% Downside)
Technical Analysis
Ironwood Pharma
―
Cumberland Pharmaceuticals
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
BioAge Labs, Inc.
―
Ownership Overview
17.06% Insiders
6.34% Mutual Funds
46.64% Other Institutional Investors
22.76% Public Companies and
Individual Investors